Molecular and Cellular Biology of Cancer Program ABSTRACT The mission of the Molecular and Cellular Biology of Cancer (MCBC) Program is to facilitate basic cancer biology research and accelerate the application of basic science discoveries into the clinic for cancer therapeutics and prevention. To achieve this, the Program brings together world-class investigators in the areas of DNA damage response and repair, RNA biology and therapeutics, cancer metabolism, and oncogenic signaling to generate synergy in the war to fight cancer. The scientific themes of the Program are 1) To define the relationship among DNA damage and repair, mutagenesis, and carcinogenesis at the molecular level and to develop therapeutic regimens based on identified targets including molecules involved in DNA damage response, repair, and epigenetic changes; 2) To define and characterize fundamental biological mechanisms for novel microRNAs and long non-coding RNAs in tumor initiation, development, and metastasis as well as to develop technology based on non-coding RNAs for cancer therapeutics; and 3) To elucidate signaling pathway alterations due to metabolic imbalance that result in cancer initiation, cancer cell proliferation and/or death, and metastasis and to improve the design of cancer therapeutic regimens. Targeted recruits who are nationally prominent have brought depth and breadth to the program and include: Drs. Mark LaBarge, Kevin Morris, Zijie Sun, Debbie Thurmond, and Xiaochun Yu. The Program is led by Drs. Binghui Shen, Professor and Chair of Cancer Genetics and Epigenetics, and David Ann, Professor in the Department of Diabetes Complications and Metabolism in the Diabetes and Metabolism Research Institute. In addition to its scientific goals, the MCBC Program seeks to promote inter- and intra-programmatic collaborations, facilitate access to new technologies and resources, create forums for scientific exchange and discussion, discover and elucidate basic cancer processes that can be collaboratively translated to the clinic, and mentor the Program?s junior faculty. Membership: 25 Members representing 11 academic departments Publications: 270 total. 18.5% intra-programmatic; 39.6% inter-programmatic; 28.9% inter-institutional Funding: $8,175,843 peer-reviewed; $3,301,399 of which is NCI funding

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beckman Research Institute/City of Hope
United States
Zip Code
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Wu, Chenkai; Ashing, Kimlin Tam; Jones, Veronica C et al. (2018) The association of neighborhood context with health outcomes among ethnic minority breast cancer survivors. J Behav Med 41:52-61
Wussow, Felix; Chiuppesi, Flavia; Meng, Zhuo et al. (2018) Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex. J Virol Methods 251:30-37
Kingsmore, Kathryn M; Vaccari, Andrea; Abler, Daniel et al. (2018) MRI analysis to map interstitial flow in the brain tumor microenvironment. APL Bioeng 2:
Paz, Helicia; Joo, Eun Ji; Chou, Chih-Hsing et al. (2018) Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008. J Exp Clin Cancer Res 37:67
Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2018) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer 17:235-245
Wildes, Tanya M; Maggiore, Ronald J; Tew, William P et al. (2018) Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research Group. Support Care Cancer 26:3563-3570
Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828

Showing the most recent 10 out of 1396 publications